Research Papers: Gerotarget (Focus on Aging):

Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation

Daniele Pastori, Pasquale Pignatelli, Alessio Farcomeni, Cristina Nocella, Simona Bartimoccia, Roberto Carnevale and Francesco Violi _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:39143-39147. https://doi.org/10.18632/oncotarget.9826

Metrics: PDF 703 views  |   HTML 1138 views  |   ?  


Daniele Pastori1,*, Pasquale Pignatelli1,*, Alessio Farcomeni2, Cristina Nocella1, Simona Bartimoccia1, Roberto Carnevale3 and Francesco Violi1

1 I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy

2 Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Rome, Italy

3 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy

* These authors have contributed equally to this work

Correspondence to:

Francesco Violi, email:

Keywords: atrial fibrillation, aging, thromboxane, cardiovascular disease, platelet, Gerotarget

Received: March 07, 2016 Accepted: May 12, 2016 Published: June 06, 2016


Aging is strictly associated with an increased incidence of cardiovascular events (CVEs) in the general population. Mechanisms underlying the risk of CVEs are still unclear. Platelet activation contributes to the onset of cardiovascular complications. The incidence of atrial fibrillation (AF) increases with age, and the natural history of AF is often complicated by CVEs. We prospectively investigated the relationship between age, urinary thromboxane (Tx) B2, which reflects platelet activation, and CVEs in 833 AF patients. Median TxB2 level was 120 [66-200] ng/mg of urinary creatinine. At multivariable linear regression analysis, age (B: 0.097, p=0.005) and previous MI/CHD (B: 0.069, p=0.047) were associated with log-TxB2 levels. When we divided our population into age classes (i.e. < 60, 60-69, 70-79, ≥ 80 years), we found a significant difference in TxB2 levels across classes (p=0.005), with a significant elevation at 74.6 years. During a mean follow-up of 40.9 months, 128 CVEs occurred; the rate of CVEs significantly increased with age classes (Log-rank test, p < 0.001). TxB2 levels were higher in patients with, compared to those without, CVEs in patients aged 70-79 (p < 0.001) and ≥ 80 (p = 0.020) years. In conclusion, TxB2 levels enhance by increasing age, suggesting that platelet activation contributes to CVEs in elderly patients with AF.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9826